For the quarter ended June 2025, SurModics (SRDX) reported revenue of $29.57 million, down 2.6% over the same period last year. EPS came in at $0.06, compared to -$0.27 in the year-ago quarter.
The reported revenue represents a surprise of +4.29% over the Zacks Consensus Estimate of $28.35 million. With the consensus EPS estimate being -$0.21, the EPS surprise was +128.57%.
While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how they compare to Wall Street expectations to determine their next course of action, some key metrics always provide a better insight into a company's underlying performance.
Since these metrics play a crucial role in driving the top- and bottom-line numbers, comparing them with the year-ago numbers and what analysts estimated about them helps investors better project a stock's price performance.
Here is how SurModics performed in the just reported quarter in terms of the metrics most widely monitored and projected by Wall Street analysts:
- Revenue- Product sales: $16.76 million versus the two-analyst average estimate of $15.69 million. The reported number represents a year-over-year change of -4.6%.
- Revenue- Research, development and other: $3.15 million compared to the $2.37 million average estimate based on two analysts. The reported number represents a change of +35.7% year over year.
- Revenue- Royalties and license fees: $9.66 million versus $10.2 million estimated by two analysts on average. Compared to the year-ago quarter, this number represents a -7.7% change.
View all Key Company Metrics for SurModics here>>>
Shares of SurModics have returned +12.9% over the past month versus the Zacks S&P 500 composite's +1.9% change. The stock currently has a Zacks Rank #5 (Strong Sell), indicating that it could underperform the broader market in the near term.
Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report
Surmodics, Inc. (SRDX): Free Stock Analysis ReportThis article originally published on Zacks Investment Research (zacks.com).
Zacks Investment Research
